Pharmacogenomics in migrane: Catching biomarkers for a predictable disease control

Expert Review of Neurotherapeutics

Volumn 9, Issue 9, 2009, Pages 1267-1269

  Simmaco, Maurizio ^a   Borro, Marina ^a   Missori, Serena ^a   Martelletti, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOCHROME P450; MONOAMINE OXIDASE A INHIBITOR; SEROTONIN ANTAGONIST; TRIPTAN DERIVATIVE;

DRUG MECHANISM; DRUG TARGETING; EDITORIAL; EPIGENETICS; HUMAN; MIGRAINE; PHARMACOGENOMICS; DRUG DESIGN; GENE THERAPY; GENETIC MARKER; GENETICS; METHODOLOGY; PHARMACOGENETICS;

DRUG DESIGN; GENE THERAPY; GENETIC MARKERS; HUMANS; MIGRAINE DISORDERS; PHARMACOGENETICS;

EID: 70349473208     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.80     Document Type: Editorial

References (15)

1. Farinelli I, Missori S, Martelletti P. Proinflammatory mediators and migraine pathogenesis: moving towards CGRP as a target for a novel therapeutic class. Expert Rev. Neurother. 8(9), 1347-1354 (2008).
2. Piane M, Lulli P, Farinelli I et al. Genetics of migraine and pharmacogenomics: some considerations. J. Headache Pain 8(6), 334-339 (2007).
3. Montagna P. The primary headaches: genetics, epigenetics and behavioural genetic model. J. Headache Pain 9(2), 57-69 (2008). • Comprehensive review on the future evolution of genetics research in headache.
4. Schürks M. Epigenetics in primary headaches: a new avenue for research. J. Headache Pain 9(3) 191-192 (2008).
5. Montagna P. Epigenetics and pharmacoepigenetics in the primary headaches. J. Headache Pain 9(3) 193-194 (2008).
6. Tfelt-hansen P, Brøsen K. Pharmacogenomics and migraine: possible implications. J. Headache Pain 9(1), 13-18 (2008). • Understanding how pharmacogenomics will change headache therapy.
7. Russell MB. Genetics in primary headaches. J. Headache Pain 8(3), 190-195 (2007).
8. Mennini FS, Gitto L, Martelletti P. Improving care through health economic analyses: cost of illness and headache. J. Headache Pain 9, 199-206 (2008).
9. Armstrong SC, Cozza KL. Triptans. Psychosomatics 43(6), 502-504 (2002).
10. Johnson MP, Fernandez F, Colson NJ et al. A pharmacogenomic evaluation of migraine therapy. Expert Opin. Pharmacother. 8(12), 1821-1835 (2007).
11. Ferrari A, Spaccapelo L, Gallesi G, Sternieri E. Focus on headache as an adverse reaction to drugs. J. Headache Pain 10, 235-239 (2009).
12. Fernandez F, Colson NJ, Griffiths LR. Pharmacogenetics of migraine: genetic variants and their potential role in migraine therapy. Pharmacogenomics 8(6), 609-622 (2007). (Pubitemid 46939586)
13. Borro M, Gentile G, Stigliano A, Misiti S, Toscano V, Simmaco M. Proteomic analysis of peripheral T lymphocytes, suitable circulating biosensors of strictly related diseases. Clin. Exp. Immunol. 150(3), 494-501 (2007). (Pubitemid 350098726)
14. Steiner TJ, Paemeleire K, Jensen R et al. European principles of management of common headache disorders in primary care. J. Headache Pain 8(Suppl. 1), S3-S47 (2007). • The last cornerstone on the management of headache disorders. (Pubitemid 350182701)
15. WHO Global Campaign to Reduce the Burden of Headache Worldwide "Lifting The Burden" www.who.int/mental-health/neurology/headache/en/